BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/18/2025 8:12:16 AM | Browse: 206 | Download: 961
 |
Received |
|
2024-08-13 14:45 |
|
Peer-Review Started |
|
2024-08-13 14:45 |
|
First Decision by Editorial Office Director |
|
2024-11-11 07:27 |
|
Return for Revision |
|
2024-11-11 07:27 |
|
Revised |
|
2024-11-27 07:12 |
|
Publication Fee Transferred |
|
2024-11-28 13:35 |
|
Second Decision by Editor |
|
2024-12-10 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-10 06:15 |
|
Articles in Press |
|
2024-12-10 06:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-17 09:07 |
|
Publish the Manuscript Online |
|
2025-01-18 08:12 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Retrospective Study |
| Article Title |
Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee and Jin-Hyeok Hwang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jaihwan Kim, MD, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Seongnam 13620, South Korea. drjaihwan@snu.ac.kr |
| Key Words |
Pancreatic cancer; Chemotherapy; Survival; Performance status; Carbohydrate antigen 19-9 |
| Core Tip |
This study retrospectively analyzed 141 patients with advanced pancreatic cancer treated between 2012 and 2021, who underwent first-line oxaliplatin or gemcitabine plus nab-paclitaxel, followed by third-line chemotherapy. The median overall survival was 19 months, with 15.3 weeks after third-line treatment. The study identified that patients with good performance status, carbohydrate antigen 19-9 < 1000 U/mL, second-line chemotherapy ≥ 19 weeks, and no peritoneal seeding before starting third-line treatment had better outcomes regardless of the third-line regimen. These findings suggest that such patients may benefit more from third-line chemotherapy in spite of unsatisfactory treatment results from all patients. |
| Publish Date |
2025-01-18 08:12 |
| Citation |
Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. World J Gastrointest Oncol 2025; 17(2): 100167 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i2.100167 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
